Ipilimumab and Nivolumab Followed by Adjuvant Nivolumab in Locally Advanced or Limited Metastatic Melanoma
European Institute of Oncology
European Institute of Oncology
University of Chile
Pliant Therapeutics, Inc.
The University of Queensland
University of Kansas Medical Center
RemeGen Co., Ltd.
Herlev Hospital
Centre Hospitalier Universitaire de Nice
JS InnoPharm, LLC
University Hospital Rijeka
Institute of Oncology Ljubljana
Assistance Publique - Hôpitaux de Paris
Peter MacCallum Cancer Centre, Australia
Leiden University Medical Center
Provectus Pharmaceuticals
The Netherlands Cancer Institute
OncoResponse, Inc.
Universitair Ziekenhuis Brussel
Massachusetts General Hospital
University of Utah
Karolinska University Hospital
Keio University
Massachusetts General Hospital
Centre Hospitalier Universitaire Vaudois
Biocad
Bio-Thera Solutions
Melanoma Institute Australia
The Christie NHS Foundation Trust
Region Stockholm
Biocad
Kineta Inc.
BGI, China
Fujian Cancer Hospital
NovalGen Ltd.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
PrimeVax Immuno-Oncology Inc.
The Netherlands Cancer Institute
Fudan University
Peking University Cancer Hospital & Institute
Regina Elena Cancer Institute
Western Sydney Local Health District
Shanghai Kechow Pharma, Inc.
Qilu Pharmaceutical Co., Ltd.
Batroussy, Rafik
University Hospital, Essen
Fudan University
Assistance Publique Hopitaux De Marseille
Hoosier Cancer Research Network
BGI, China
Peking University Cancer Hospital & Institute